SCHEMBL7904241

SCHEMBL7904241

CCc1ccc2c(c1)C(=O)N(C)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.47
HTR2C P28335 2/20 0.47
HTR2B P41595 2/20 0.47
GABRA1 P14867 5/20 0.45
GABRA5 P31644 5/20 0.45
GABRG2 P18507 4/20 0.45
GABRB3 P28472 4/20 0.45
GABRA3 P34903 4/20 0.45
GABRA2 P47869 4/20 0.45
GABRA6 Q16445 4/20 0.45
GABRB2 P47870 2/20 0.45
DDB1 Q16531 2/20 0.45
CRBN Q96SW2 2/20 0.45
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17208003 0.88 DDB1 (0.46) HTR2AHTR2CHTR2BDDB1CRBN
SCHEMBL7895567 0.86 HTR2A (0.47) HTR2AHTR2CHTR2BGABRA1GABRA5
SCHEMBL23981898 0.85 DDB1 (0.44) HTR2AHTR2CHTR2BGABRA1GABRA5
SCHEMBL29289728 0.85 DDB1 (0.44) HTR2AHTR2CHTR2BGABRA1GABRA5
SCHEMBL8218196 0.83 HTR2A (0.51) HTR2AHTR2CHTR2BDDB1CRBN
SCHEMBL18848849 0.82 DDB1 (0.42) HTR2AHTR2CHTR2BDDB1CRBN
SCHEMBL25060995 0.82 DDB1 (0.42) HTR2AHTR2CHTR2BGABRA1GABRA5
SCHEMBL24221625 0.82 SDCBP (0.43) GABRA1GABRB2DDB1CRBNMAPT
SCHEMBL7903003 0.82 ALDH1A1 (0.45) HTR2AHTR2CHTR2BALDH1A1NPC1
SCHEMBL18616795 0.80 ALDH1A1 (0.43) HTR2AHTR2CHTR2BGABRA1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 US disclosed
WO-2021226003-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-11-11 WO disclosed
US-20210347772-A1 AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-11-11 US disclosed
US-9896443-B2 Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof PETER MACCALLUM CANCER INSTITUTE (AU) 2018-02-20 US disclosed
US-20150218150-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2015-08-06 US disclosed
WO-2010065717-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF KRAS, VHL, HRAS HTR2A 4692/4885HTR2C 4755/4885HTR2B 4817/4885
US-20210347772-A1 AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 LRRK2, PARK7, GDI2 HTR2A 1061/4885HTR2C 1918/4885HTR2B 2164/4885
US-20150218150-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PRF1, GZMB, BAK1 HTR2A 1175/4885HTR2C 831/4885HTR2B 1128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.